Table 3.
Multivariable linear regression model of MIBS-4 scores (interictal burden). A positive estimate suggests the characteristic is associated with worse interictal burden; a negative estimate suggests it is associated with lower interictal burden
| Characteristic | Estimate | SE | 95% CIa | p-valuea |
|---|---|---|---|---|
| HIT-6 score | 0.14 | 0.02 | 0.10, 0.19 | < 0.001 |
| Monthly migraine day | 0.09 | 0.03 | 0.04, 0.15 | < 0.001 |
| Monthly headache day | 0.07 | 0.02 | 0.02, 0.12 | 0.003 |
| Depression | ||||
| No | 0.00 | – | – | – |
| Yes | 0.74 | 0.34 | 0.08, 1.40 | 0.03 |
| Anxiety | ||||
| No | 0.00 | – | – | – |
| Yes | 0.00 | 0.34 | −0.67, 0.66 | > 0.9 |
| Employment status | ||||
| Part−/Full-time | 0.00 | – | – | – |
| Otherb | − 0.41 | 0.35 | −1.09, 0.27 | 0.24 |
| Retired | −0.72 | 0.44 | −1.59, 0.15 | 0.11 |
| Satisfied with treatment regimenc | ||||
| No | 0.00 | – | – | – |
| Yes | −0.30 | 0.26 | −0.81, 0.20 | 0.24 |
| CGRP mAb treatment (3+ months) | ||||
| In the last 3 months | 0.00 | – | – | – |
| In the past | 0.69 | 0.41 | −0.11, 1.50 | 0.09 |
| Never | −1.42 | 0.37 | −2.14, −0.69 | < 0.001 |
| Sex | ||||
| Male | 0.00 | – | – | – |
| Female | −0.37 | 0.27 | −0.91, 0.17 | 0.18 |
| Age (years) | −0.02 | 0.01 | −0.04, 0.01 | 0.15 |
| Country | ||||
| US | 0.00 | – | – | – |
| Germany | 0.48 | 0.28 | −0.07, 1.03 | 0.09 |
R2 = 0.358; Adjusted R2 = 0.341; Statistic = 21.1; p-value = < 0.001; AIC = 2490; BIC = 2554; N = 506
CGRP Calcitonin-gene related peptide, CI Confidence Interval, HIT-6 Headache Impact Test, mAb monoclonal antibody, SE Standard Error
a95% CIs and p-values are exploratory
bUnemployed, unable to work due to health issues, student, homemaker, other
cYes: Satisfied or very satisfied with all treatments taken (acute/preventive/CGRP mAb treatment)